HRP20231588T3 - Kombinacija koja sadrži stabilni kristal 4-oksokinolinskog spoja - Google Patents

Kombinacija koja sadrži stabilni kristal 4-oksokinolinskog spoja

Info

Publication number
HRP20231588T3
HRP20231588T3 HRP20231588TT HRP20231588T HRP20231588T3 HR P20231588 T3 HRP20231588 T3 HR P20231588T3 HR P20231588T T HRP20231588T T HR P20231588TT HR P20231588 T HRP20231588 T HR P20231588T HR P20231588 T3 HRP20231588 T3 HR P20231588T3
Authority
HR
Croatia
Prior art keywords
crystal
ray powder
combination
pharmaceutical preparation
stable crystal
Prior art date
Application number
HRP20231588TT
Other languages
English (en)
Inventor
Motohide Satoh
Takahisa Motomura
Takashi Matsuda
Kentaro Kondo
Koji Ando
Koji Matsuda
Shuji Miyake
Hideto Uehara
Original Assignee
Japan Tobacco, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20231588(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco, Inc. filed Critical Japan Tobacco, Inc.
Publication of HRP20231588T3 publication Critical patent/HRP20231588T3/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (3)

1. Farmaceutski pripravak, naznačen time što sadrži: (a) kristal (kristalni oblik II) 6-(3-klor-2-fluorbenzil)-1-[(S)-1-hidroksimetil-2-metilpropil]-7-metoksi-4-okso-1,4-dihidrokinolin-3-karboksilne kiseline, koji ima uzorak difrakcije rendgenskih zraka na prahu koji ima karakteristične difrakcijske maksimume pod difrakcijskim kutevima 2θ (°) od 6,56, 13,20, 19,86, 20,84, 21,22, 25,22, kao što su izmjereni difraktometrom rendgenskih zraka na prahu, ili (b) kristal (kristalni oblik III) 6-(3-klor-2-fluorbenzil)-1-[(S)-1-hidroksimetil-2-metilpropil]-7-metoksi-4-okso-1,4-dihidrokinolin-3-karboksilne kiseline, koji ima uzorak difrakcije rendgenskih zraka na prahu koji ima karakteristične difrakcijske maksimume pod difrakcijskim kutevima 2θ (°) od 8,54, 14,02, 15,68, 17,06, 17,24, 24,16, 25,74, kao što su izmjereni difraktometrom rendgenskih zraka na prahu, ili (c) miješani kristal, koji sadrži kristal gore spomenutog (a) i kristal gore spomenutog (b), te GS-7340.
2. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži farmaceutski prihvatljivi nosač.
3. Farmaceutski pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je namijenjen upotrebi u liječenju HIV-a.
HRP20231588TT 2004-05-20 2005-05-19 Kombinacija koja sadrži stabilni kristal 4-oksokinolinskog spoja HRP20231588T3 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004150979 2004-05-20
EP17186674.2A EP3281939B1 (en) 2004-05-20 2005-05-19 Combination comprising a stable crystal of a 4-oxoquinoline compound

Publications (1)

Publication Number Publication Date
HRP20231588T3 true HRP20231588T3 (hr) 2024-03-15

Family

ID=35079161

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20231588TT HRP20231588T3 (hr) 2004-05-20 2005-05-19 Kombinacija koja sadrži stabilni kristal 4-oksokinolinskog spoja
HRP20120681TT HRP20120681T1 (hr) 2004-05-20 2012-08-24 Stabilni kristal 4-oksokinolinskog spoja

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20120681TT HRP20120681T1 (hr) 2004-05-20 2012-08-24 Stabilni kristal 4-oksokinolinskog spoja

Country Status (33)

Country Link
US (6) US7635704B2 (hr)
EP (4) EP4299563A3 (hr)
JP (1) JP3754064B2 (hr)
KR (1) KR20080064909A (hr)
CN (1) CN1956961B (hr)
AR (2) AR049280A1 (hr)
AU (1) AU2005245296B2 (hr)
BR (1) BRPI0510114B8 (hr)
CA (1) CA2566922C (hr)
CY (1) CY1113010T1 (hr)
DK (2) DK3281939T3 (hr)
ES (2) ES2388441T3 (hr)
FI (2) FI3281939T3 (hr)
FR (1) FR23C1040I1 (hr)
HK (1) HK1083341A1 (hr)
HR (2) HRP20231588T3 (hr)
HU (2) HUE064615T2 (hr)
IL (1) IL179250A0 (hr)
LT (1) LT3281939T (hr)
LU (1) LUC00334I2 (hr)
MX (1) MXPA06013405A (hr)
MY (1) MY134672A (hr)
NO (6) NO339223B1 (hr)
NZ (1) NZ551839A (hr)
PE (2) PE20120361A1 (hr)
PL (2) PL1636190T3 (hr)
PT (2) PT3281939T (hr)
RS (2) RS52375B (hr)
RU (1) RU2330845C1 (hr)
SI (2) SI1636190T1 (hr)
TW (1) TWI329015B (hr)
WO (1) WO2005113508A1 (hr)
ZA (1) ZA200610647B (hr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
BRPI0306214B1 (pt) * 2002-11-20 2017-08-08 Japan Tobacco Inc. 4-oxoquinoline compound and use of this as a hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EP1976517A1 (en) * 2005-12-30 2008-10-08 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EP2452682A1 (en) * 2006-02-01 2012-05-16 Japan Tobacco, Inc. Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
US8420821B2 (en) 2006-03-06 2013-04-16 Japan Tobacco Inc. Process for production of 4-oxoquinoline compound
IN2014CN00613A (hr) 2006-03-06 2015-08-21 Japan Tobacco Inc
PT2487165T (pt) 2006-07-07 2016-11-18 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
PT2069280E (pt) 2006-09-12 2015-06-08 Gilead Sciences Inc Processo e intermediários para preparar inibidores de integrase de vih
ES2601820T3 (es) 2007-02-23 2017-02-16 Gilead Sciences, Inc. Moduladores de propiedades terapéutica de las farmacocinéticas
US20110009411A1 (en) * 2007-06-29 2011-01-13 Gilead Sciences ,Inc. Therapeutic compositions and the use thereof
KR20100040892A (ko) * 2007-06-29 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료 조성물 및 그의 용도
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
SI2296633T1 (sl) 2008-05-02 2015-11-30 Gilead Sciences, Inc. Uporaba trdnih nosilnih delcev za izboljšanje predelovalnih sposobnosti farmacevtskega sredstva
KR101738325B1 (ko) 2009-02-06 2017-05-19 길리애드 사이언시즈, 인코포레이티드 조합 요법용 정제
WO2010137032A2 (en) * 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
EP2870138B1 (en) 2012-07-06 2018-08-22 Genentech, Inc. N-substituted benzamides and methods of use thereof
BR112015002275A2 (pt) 2012-08-03 2017-07-04 Gilead Sciences Inc processos e intermediários para a preparação de inibidores da integrase
CN103819402B (zh) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 埃替拉韦中间体及其制备方法和应用
CN103864682B (zh) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 一种制备iii型埃替拉韦晶体的方法
MD4841B1 (ro) 2012-12-21 2023-01-31 Gilead Sciences, Inc. Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
NO2865735T3 (hr) 2013-07-12 2018-07-21
EP3252058B1 (en) 2013-07-12 2021-01-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
CN105315203A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种v型埃替拉韦晶体及其制备方法
NO2717902T3 (hr) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
SG11201707905WA (en) 2015-04-02 2017-10-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN106008195B (zh) * 2016-05-19 2018-08-03 绍兴文理学院 一种2，4-二氟-5-碘苯甲酸的制备方法
EP3984536A1 (en) * 2020-10-19 2022-04-20 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS567162B1 (hr) 1970-09-14 1981-02-16
JPS4826772A (hr) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (ja) 1989-07-31 1994-07-06 新日本製鐵株式会社 プラズマアーク溶接方法および装置
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
NO304832B1 (no) * 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
CA2194435A1 (en) * 1994-07-18 1996-02-01 Tomio Kimura Trifluoromethylquinolinecarboxylic acid derivative
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
EP0892801B1 (en) 1996-04-12 2002-01-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Acridone-derived compounds useful as antineoplastic and antiretroviral agents
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
GB9721964D0 (en) * 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
PE20011349A1 (es) * 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
JP2004513134A (ja) 2000-10-12 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルケトン類
WO2002055079A2 (en) 2000-10-12 2002-07-18 Merck & Co Inc Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
EP2033952B1 (en) 2001-03-01 2012-08-29 Shionogi&Co., Ltd. Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (fr) 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
JP4035765B2 (ja) 2002-10-31 2008-01-23 横河電機株式会社 フーリエ変換型赤外線分光計
BRPI0306214B1 (pt) * 2002-11-20 2017-08-08 Japan Tobacco Inc. 4-oxoquinoline compound and use of this as a hiv integrase inhibitor
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
WO2005112930A1 (en) * 2004-05-21 2005-12-01 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents

Also Published As

Publication number Publication date
DK1636190T3 (da) 2012-09-24
FIC20240008I1 (fi) 2024-03-20
RU2330845C1 (ru) 2008-08-10
PL3281939T3 (pl) 2024-03-18
EP4299563A2 (en) 2024-01-03
TWI329015B (en) 2010-08-21
NO347902B1 (no) 2024-05-06
EP2514746A1 (en) 2012-10-24
RS64845B1 (sr) 2023-12-29
TW200600097A (en) 2006-01-01
IL179250A0 (en) 2007-03-08
SI3281939T1 (sl) 2024-02-29
JP2006001927A (ja) 2006-01-05
NO20065790L (no) 2007-02-07
NO20161297A1 (no) 2007-02-07
AU2005245296A1 (en) 2005-12-01
KR20080064909A (ko) 2008-07-09
PE20060358A1 (es) 2006-05-12
NO20230913A1 (no) 2007-02-07
DK3281939T3 (da) 2024-01-22
HRP20120681T1 (hr) 2012-09-30
SI1636190T1 (sl) 2012-09-28
EP1636190A1 (en) 2006-03-22
BRPI0510114B8 (pt) 2021-05-25
US20220235009A1 (en) 2022-07-28
US20150361044A1 (en) 2015-12-17
NO20200873A1 (no) 2007-02-07
PT1636190E (pt) 2012-08-20
PL1636190T3 (pl) 2012-10-31
AU2005245296B2 (en) 2010-08-12
BRPI0510114A (pt) 2007-09-25
MXPA06013405A (es) 2007-03-01
CN1956961A (zh) 2007-05-02
US20100204271A1 (en) 2010-08-12
EP4299563A3 (en) 2024-02-28
FR23C1040I1 (fr) 2023-12-29
NO339223B1 (no) 2016-11-21
AR049280A1 (es) 2006-07-12
WO2005113508A1 (en) 2005-12-01
CY1113010T1 (el) 2016-04-13
US7635704B2 (en) 2009-12-22
PE20120361A1 (es) 2012-05-03
CA2566922A1 (en) 2005-12-01
HK1083341A1 (en) 2006-06-30
EP1636190B1 (en) 2012-06-27
US20190185433A1 (en) 2019-06-20
AR096100A2 (es) 2015-12-09
EP3281939B1 (en) 2023-10-18
CA2566922C (en) 2011-01-11
US8981103B2 (en) 2015-03-17
US20060030710A1 (en) 2006-02-09
HUE064615T2 (hu) 2024-04-28
ES2388441T3 (es) 2012-10-15
PT3281939T (pt) 2023-11-22
MY134672A (en) 2007-12-31
FI3281939T3 (fi) 2023-10-23
JP3754064B2 (ja) 2006-03-08
ZA200610647B (en) 2008-06-25
RS52375B (en) 2012-12-31
NO20220690A1 (no) 2007-02-07
HUS2400006I1 (hu) 2024-04-28
NZ551839A (en) 2009-11-27
EP3281939A1 (en) 2018-02-14
ES2960824T3 (es) 2024-03-06
NO20190051A1 (no) 2007-02-07
LT3281939T (lt) 2023-11-27
US20180029989A1 (en) 2018-02-01
LUC00334I2 (hr) 2024-07-01
CN1956961B (zh) 2010-05-26
BRPI0510114B1 (pt) 2020-09-15

Similar Documents

Publication Publication Date Title
HRP20231588T3 (hr) Kombinacija koja sadrži stabilni kristal 4-oksokinolinskog spoja
JP2018158949A5 (hr)
NZ594589A (en) 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents
IL181298A0 (en) Solid and crystalline ibandronate sodium and processes for preparation thereof
HRP20160654T1 (hr) 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
MA28451B1 (fr) Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
MA30464B1 (fr) Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
RS50599B (sr) KRISTALNI OBLIK BETA-d IVABRADIN HLORHIDRATA, POSTUPAK NJEGOVE IZRADE I FARMACEUTSKE SMEŠE KOJE GA SADRŽE
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
CA2481848A1 (en) Active ingredient particles carrying clopidogrel or a salt thereof, their use and method of preparation
CA2378382A1 (en) Carboxylic acid amides, pharmaceutical compositions containing these compounds, the use and preparation thereof
CA2453917A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
HRP20040107B1 (hr) Stabilni polimorf flibanserina, tehnički postupak njegova pripravljanja, te njegova primjena u proizvodnji lijekova
HUP0402129A3 (en) Crystalline hydrates of nicotinic acid anilide and benzoyl anilide derivatives, preparation thereof, compositions containing the same and processes for their use
JP2011527299A5 (hr)
CA2441613A1 (en) Novel amlodipine camsylate and method for preparing thereof
HRP20120700T1 (hr) SOLI SPOJEVA INHIBITORA HIV-a
FR2999086B1 (fr) Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
HRP20121074T1 (hr) Derivati kinolina i njihovi farmaceutski sastavi
WO2008077810A3 (en) Spiro-piperidine derivatives
WO2007080324A3 (fr) Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
WO2010140139A3 (en) Crystalline forms of 6-(1h- imadazol- 1-yl) -2-phenylquinazoline
EE200300461A (et) Alginaadi kasutamine pH-st sõltuva geelistuva ainena parakvatisoola, dikvatisoola või nende segu sisaldava koostise valmistamiseks
IL176870A0 (en) Solid forms of montelukast acid, pharmaceutical compositions containing the same and processes for the preparation thereof